There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and 2seventy bio (TSVT – Research Report) with bullish sentiments.
Sarepta Therapeutics (SRPT)
SVB Securities analyst Joseph Schwartz reiterated a Buy rating on Sarepta Therapeutics today and set a price target of $160.00. The company’s shares closed last Friday at $128.56, close to its 52-week high of $134.08.
According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $149.27 average price target, which is a 16.3% upside from current levels. In a report issued on January 5, RBC Capital also maintained a Buy rating on the stock with a $204.00 price target.
See the top stocks recommended by analysts >>
2seventy bio (TSVT)
In a report released today, Salveen Richter from Goldman Sachs maintained a Buy rating on 2seventy bio, with a price target of $28.00. The company’s shares closed last Friday at $10.57, close to its 52-week low of $8.44.
According to TipRanks.com, Richter is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for 2seventy bio with a $29.50 average price target, which is a 196.5% upside from current levels. In a report issued on January 5, SVB Securities also maintained a Buy rating on the stock with a $41.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SRPT:
- UBS Says These 2 Stocks Offer Attractive Risk-Reward Right Now — Here’s Why
- Sarepta price target raised to $125 from $114 at Cowen
- Sarepta price target raised to $160 from $158 at Needham
- Sarepta price target raised to $114 from $101 at Credit Suisse
- Sarepta expects to exceed FY22 guidance for net product revenues
